Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) (HIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00790894

Recruitment Status : Terminated (The low accrual rate of the study (25% of the expected accrual rate))

First Posted : November 14, 2008

Last Update Posted : May 18, 2011

Sponsor:

Information provided by:

Hellenic Cooperative Oncology Group

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	April 2011
Actual Study Completion Date :	May 2011

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, Bobos M, Mavropoulou X, Papadimitriou C, Vrettou E, Raptou G, Koutras A, Razis E, Bafaloukos D, Samantas E, Pentheroudakis G, Skarlos DV. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One. 2013 Jul 23;8(7):e69256. doi: 10.1371/journal.pone.0069256. Print 2013.

To Top